concept

synthetic lethality

Also known as: synthetic lethal therapeutic strategies, synthetic lethal approaches, synthetic lethal agents, synthetic lethal strategies

from single model dimension

No definition has been generated yet — showing the first model analysis as a summary.

Synthetic lethality is a genetic phenomenon where defects in two or more genes together cause cell death or apoptosis, but individual defects do not, as first observed by Calvin Bridges in Drosophila melanogaster in the 1920s and formalized by Theodore Dobzhansky in Drosophila pseudoobscura. cell death from dual gene defects In cancer therapy, it exploits tumor-specific vulnerabilities to selectively kill cancer cells with fewer side effects than chemotherapy, often targeting DNA damage response (DDR) pathways by inhibiting genes like PARP, ATR, ATM, WEE1, and PRMT, or inducing lethality in cells with TP53, ARID1A, or ATM mutations. cancer-specific genetic vulnerabilities conventional gene targets PARP ATR disrupts DNA repair in cancer Examples include WRN helicase deletion in microsatellite unstable tumors and CIP2A identified by Daniel Durocher et al. via CRISPR-Cas9 screens in BRCA-mutant cells. WRN helicase in MSI tumors Classified into unconditional and conditional types, it is extensively studied in ovarian and breast cancers but underexplored elsewhere, with top clinical trials in lymphoma, colorectal, lung, ovarian, and breast cancers; SL trials show higher success rates, with about one-third beyond DDR per Trialtrove database analysis. SL trials higher success rate Challenges include identifying lethal partners, biomarker validation, drug development, resistance, and tumor heterogeneity. technical challenges identifying partners Tools like the Synthetic Lethality Knowledge Graph (SLKG) by researchers and SLOAD database integrating Li Guo et al.'s data aid discovery. Future integration with immunotherapy, multi-omics, and AI promises precision oncology advances, with rising SL trials since PARP inhibitors for BRCA-mutated breast cancer and new biotech firms. SLKG identifies cancer treatments

Model Perspectives (3)

openrouter/x-ai/grok-4.1-fast definitive 95% confidence

openrouter/x-ai/grok-4.1-fast definitive 88% confidence

Synthetic lethality (SL) is a genetic principle where the co-occurrence of two non-lethal perturbations, such as mutations or inhibitions, results in cell death, enabling selective targeting of cancer cells with specific vulnerabilities while sparing normal cells. According to Nijman SM (2011), SL involves general principles and detection via genetic screens in human cells. Early work by Lucchesi JC (1968) explored it in Drosophila mutants. In cancer therapy, SL drives precision oncology by identifying biomarkers, targets, and combinations, as noted by Huang et al. (2020). Examples include ATR inhibitors inducing SL in ARID1A-deficient tumors (Shibata et al., implied 2016) and mismatch repair-deficient cells (Kim et al., implied), or MRTX1719 exhibiting SL in MTAP-deleted cancers per Engstrom et al. (2023). Since 2016, biotech firms have advanced SL drugs for metabolic targets, DNA repair inhibitors, and CRISPR-based discovery (claim on biotech wave). Challenges include drug resistance (challenge of resistance), tumor heterogeneity (tumor heterogeneity impact), and needs for combinations with chemo or immunotherapy (need for combinations) and biomarkers (biomarker identification). It promises improved specificity, reduced toxicity, and personalized treatment as research progresses (future expectations).

openrouter/x-ai/grok-4.1-fast 95% confidence

Synthetic lethality refers to genetic interactions where the combined disruption of two genes or pathways is lethal to cells, particularly exploited in cancer therapy to target tumors with specific vulnerabilities while sparing normal cells. Researchers have identified numerous synthetic lethal partners in cancer contexts, such as proteases with PI3K inhibition in breast cancer via RNA interference screens by Hölzen et al. (2022), Wnt signaling with Rb inactivation via TORC1 reported by Zhang T et al. (2014) in PLoS Genetics, and CIP2A-TOPBP1 axis in BRCA-mutated cancers by Adam S et al. (2021) in Nature Cancer. Additional examples include FEN1 and APEX2 as BRCA2 targets from Mengwasser et al. (2019) and Wnt activation with asparaginase in leukemias by Hinze L et al. (2019). Reviews highlight its application in cancers with PTEN loss (Ertay et al.), DNA repair mechanisms (Watanabe and Seki 2024), and precision oncology landscapes (Schäffer et al. 2024). Methods for discovery include systematic pathway profiling by Chang L et al. and computational prediction via ELISL by Tepeli et al. (2024). Overall, the facts portray synthetic lethality as a cornerstone of targeted cancer therapies, with ongoing systematic analyses and evolving targets in DNA repair and pathway dysregulation.

Facts (1)

Sources

Perspectives on cancer therapy—synthetic lethal precision medicine ... nature.com Nature Apr 16, 2025 1 fact

referenceThe 2022 review 'Evolving DNA repair synthetic lethality targets in cancer' published in Bioscience Reports by Kulkarni et al. discusses the development of synthetic lethality targets in cancer therapy.